7-Diethylamino-3-nitro-2-oxo-2H-chromene-4-carbonitrile | 910134-34-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 7-Diethylamino-3-nitro-2-oxo-2H-chromene-4-carbonitrile
• CAS: 910134-34-8
• 化学式: C₁₄H₁₃N₃O₄
• 分子量: 287.275
• InChiKey: LXGWWYFJXZDSMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.42
• 重原子数：
  21.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  100.38
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  7-Diethylamino-3-nitro-2-oxo-2H-chromene-4-carbonitrile 在 盐酸 、 tin(ll) chloride 作用下， 反应 4.0h， 以67%的产率得到3-Amino-7-(diethylamino)-2-oxochromene-4-carbonitrile
  参考文献：
  名称：

  Synthesis and anti-angiogenesis activity of coumarin derivatives

  摘要：

  A series of 7-diethylaminocoumarin compounds were synthesized and the cytotoxicities were tested against human umbilical vein endothelial cell (HUVEC) and some cancer cells. We found that the introduction of cyano groups at the 4-position will promote the bioactivity. In particular, compounds 9 and 10 strongly inhibited the proliferation of various cancer cell lines, and 12 and 15 showed a high selectivity for HUVEC. Therefore, these coumarin molecules can be utilized as lead compounds to develop potential nontoxic angiogenesis inhibitors and small molecular ligands to target HUVEC. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.06.007
• 作为产物：
  描述：

  4-(二乙氨基)水杨醛 在 吗啉 、 碘 、 溶剂黄146 作用下， 以 二甲基亚砜 、 正丁醇 为溶剂， 生成 7-Diethylamino-3-nitro-2-oxo-2H-chromene-4-carbonitrile
  参考文献：
  名称：

  Synthesis and anti-angiogenesis activity of coumarin derivatives

  摘要：

  A series of 7-diethylaminocoumarin compounds were synthesized and the cytotoxicities were tested against human umbilical vein endothelial cell (HUVEC) and some cancer cells. We found that the introduction of cyano groups at the 4-position will promote the bioactivity. In particular, compounds 9 and 10 strongly inhibited the proliferation of various cancer cell lines, and 12 and 15 showed a high selectivity for HUVEC. Therefore, these coumarin molecules can be utilized as lead compounds to develop potential nontoxic angiogenesis inhibitors and small molecular ligands to target HUVEC. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.06.007